ARCA biopharma, Inc. ABIO
28.80 0.00 (+0.00%)
At closeAug 30, 2024, 4:00 PM EDT
2.25 Day range 28.80
52-week range unavailable
- Market cap
- 34.82M
- Shares out
- 1.21M
- Forward P/E
- -3.27
- Volume
- 290.85K
- Open
- 2.35
- Previous close
- 28.80
- Day's range
- 2.25 – 28.80
- Beta
- 0.90
- Earnings date
- Oct 16, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- 3.01M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 12.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.98M
- Total cash
- 33.28M
- Total debt
- 24.00K
- Return on equity
- -20.05%
- Short % of float
- 48.08%
- 50-day average
- 39.21
- 200-day average
- 30.93
Analyst view
Price target (mean) —
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 16, 2024
Expected Oct 16, 2024. Consensus EPS estimate 0.00.
Financials — quick view
ABIO Revenue — quarterly 0
ABIO Net income — quarterly -2.68M
ABIO EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 16, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Apr 25, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 18, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Jul 21, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2013 | Dawson James | init | — | Buy |
About ARCA biopharma, Inc.
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcabio.com
News
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS 
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split 
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket 
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics 
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics 
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics 
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update 
Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka 
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO) 
12 Health Care Stocks Moving In Friday's Intraday Session
Your note
Sign in to keep a note on ABIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT PETER | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 25, 2018 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 25, 2018 | 0 |
| CABLE CAR CAPITAL LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 15, 2022 | 4,000,450 |
| CONWAY ROBERT E | Chairman of the Board | Purchase | May 11, 2021 | 50,000 |
| DEKKER C JEFFREY | Chief Financial Officer | Stock Award(Grant) | Dec 7, 2022 | 40,000 |
| KEUER THOMAS A | Chief Operating Officer | Stock Award(Grant) | Dec 7, 2022 | 40,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bml Capital Management, Llc | 4.91% | 706,930 | 1.44M | Jun 29, 2023 |
| Western Standard, LLC | 4.37% | 630,191 | 1.28M | Jun 29, 2023 |
| Vanguard Group Inc | 3.20% | 461,613 | 937.07K | Jun 29, 2023 |
| Newtyn Management, Llc | 2.17% | 313,200 | 635.80K | Jun 29, 2023 |
| Blackrock Inc. | 1.61% | 231,959 | 470.88K | Jun 29, 2023 |
| Geode Capital Management, LLC | 1.08% | 155,635 | 315.94K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.17% | 312,166 | 633.70K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.96% | 138,329 | 280.81K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.39% | 55,513 | 117.13K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.37% | 52,959 | 111.74K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.33% | 46,948 | 95.30K | Jun 29, 2023 |
| Tekla Life Sciences Investors | 0.23% | 32,461 | 65.89K | Jun 29, 2023 |